June 13, 2012

Treatment Options for Malignant Pleural EffusionsPatient Preference Does Matter

Author Affiliations

Author Affiliations: Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, England.

JAMA. 2012;307(22):2432-2433. doi:10.1001/jama.2012.5543

Malignant pleural effusion affects more than 150 000 patients per year in the United States, and its prevalence continues to increase.1 A malignant pleural effusion usually signifies advanced metastatic disease and is associated with a poor prognosis with median survival between 3 and 12 months, depending on the primary site.2 Lung cancer accounts for more than a third of cases of malignant effusion, with a life expectancy of less than 4 months.3,4

First Page Preview View Large
First page PDF preview
First page PDF preview